Aurore Baron

Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma

Christèle Desbois‐Mouthon, Aurore Baron, Marie-José Blivet-Van Eggelpoël et al. · Clinical Cancer Research · 2009 · 153 citations

Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

Philippe Merle, Jean‐Frédéric Blanc, Jean–Marc Phelip et al. · ˜The œLancet. Gastroenterology & hepatology · 2019 · 58 citations · Full text

Nanoparticles, Nanomedicine, Sorafenib Treatment Failure +12

Influence of hepatic dysfunction on safety, tolerability, and pharmacokinetics (PK) of PTK787/ZK 222584 in patients (Pts) with unresectable hepatocellular carcinoma (HCC)

Inga Koch, Aurore Baron, S. A. Roberts et al. · Journal of Clinical Oncology · 2005 · 38 citations

Hepatic Dysfunction, Tyrosine Kinase, Pathology +21

CA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation

Maria Jesus Jimenez Exposito, Mehmet Akce, José Luís Montero Álvarez et al. · Annals of Oncology · 2018 · 20 citations · Full text

Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting

Manon Falette-Puisieux, Jean‐Charles Nault, Mohamed Bouattour et al. · Therapeutic Advances in Medical Oncology · 2023 · 17 citations · Full text